ranibizumab   Click here for help

GtoPdb Ligand ID: 6779

Synonyms: Fab-12 variant Y0317 | Lucentis® | muMAb VEGF A.4.6.1 | rhuFab V2
Approved drug
ranibizumab is an approved drug (FDA (2006), EMA (2007))
Compound class: Antibody
Comment: Ranibizumab is a Fab fragment of a monoclonal antibody designed to target vascular endothelial growth factor A (VEGFA).
Annotated peptide sequences for this antibody derivative are available from its IMGT/mAb-DB record.
Peptide sequence analysis reveals that ranibizumab sequences are claimed in patent WO1998045331 (clone Y0317) [2], with an expected affinity similar to clone Y0313-1. It is the Fab fragment of bevacizumab.

Name(s)Trade nameCompanyClinical PhaseIndications
Razumab®Intas PharmaceuticalsApproved (India 2015)As per reference agent
SB11; ranibizumab-nunaByooviz®Samsung BioepisApproved (EMA & FDA 2021)As per reference agent
Susvimo®Genentech/RocheApproved (FDA 2021)wet AMD
FYB201; ranibizumab-eqrnCimerli®Coherus BioSciencesApproved (FDA 2022)As per reference agent
Ranivisio®Midas PharmaApproved (EMA 2022)wet AMD
Ximluci®STADA ArzneimittelApproved (EMA 2022)As per reference agent
Classification Click here for help
Compound class Antibody
Approved drug? Yes (FDA (2006), EMA (2007))
International Nonproprietary Names Click here for help
INN number INN
8313 ranibizumab
Synonyms Click here for help
Fab-12 variant Y0317 | Lucentis® | muMAb VEGF A.4.6.1 | rhuFab V2
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 84
Reactome Drug Reactome logo R-ALL-9679464
Reactome Reaction Reactome logo R-HSA-9679477
Other databases
GtoPdb PubChem SID 178103385
PubChem SID 178103385
Search PubMed clinical trials ranibizumab
Search PubMed titles ranibizumab
Search PubMed titles/abstracts ranibizumab
Wikipedia Ranibizumab